scholarly journals Relationship between stereopsis and vision-related quality of life following intravitreal ranibizumab injections for central retinal vein occlusion

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Fumiki Okamoto ◽  
Mizuki Tomioka ◽  
Tomoya Murakami ◽  
Shohei Morikawa ◽  
Yoshimi Sugiura ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Visual Acuity ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Post Treatment ◽  
Intravitreal Ranibizumab ◽  
Vein Occlusion ◽  
Related Quality ◽  
Central Retinal Vein

AbstractThe study aimed to evaluate changes in stereopsis and vision-related quality of life (VR-QOL) in patients with central retinal vein occlusion (CRVO) following intravitreal ranibizumab injection (IVR) and investigate the relationship between stereopsis and VR-QOL. This study included 23 treatment-naïve patients with non-ischemic CRVO and 13 age-matched normal controls. Stereopsis, best-corrected visual acuity (BCVA), VR-QOL, and retinal microstructures were examined pre-treatment and 12 months post-treatment. The Titmus Stereo Test (TST) and TNO stereotest (TNO) were used to evaluate stereopsis. VR-QOL was evaluated using the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25). IVR immediately and significantly improved the TST values, TNO values, composite VFQ-25 score, BCVA, and central foveal thickness in patients with CRVO. The 12-month post-treatment TST and TNO values were significantly worse in the CRVO group compared to those in the normal group. At the baseline, the composite VFQ-25 score significantly correlated only with the TST value. Multivariate analysis revealed significant associations between the 12-month post-treatment composite VFQ-25 score and the baseline and 12-month post-treatment TNO values. In conclusion, IVR immediately improved stereopsis in CRVO, albeit below normal levels. Stereopsis (not visual acuity) was associated with pre- and post-treatment VR-QOL in patients with CRVO.

scholarly journals Relationship Between Stereopsis and Vision-Related Quality of Life Following Intravitreal Ranibizumab Injections for Central Retinal Vein Occlusion

2021 ◽  
Author(s):  
Fumiki Okamoto ◽  
Mizuki Tomioka ◽  
Tomoya Murakami ◽  
Shohei Morikawa ◽  
Yoshimi Sugiura ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Visual Acuity ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Post Treatment ◽  
Intravitreal Ranibizumab ◽  
Vein Occlusion ◽  
Related Quality ◽  
Central Retinal Vein

Abstract The study aimed to evaluate changes in stereopsis and vision-related quality of life (VR-QOL) in patients with central retinal vein occlusion (CRVO) following intravitreal ranibizumab injection (IVR) and investigate the relationship between stereopsis and VR-QOL. This study included 23 treatment-naïve patients with CRVO and 13 age-matched normal controls. Stereopsis, best-corrected visual acuity (BCVA), VR-QOL, and retinal microstructures were examined pre-treatment and 12 months post-treatment. The Titmus Stereo Test (TST) and TNO stereotest (TNO) were used to evaluate stereopsis. VR-QOL was evaluated using the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25). IVR immediately and significantly improved the TST values, TNO values, composite VFQ-25 score, BCVA, and central foveal thickness in patients with CRVO. The 12-month post-treatment TST and TNO values were significantly worse in the CRVO group compared to those in the normal group. The baseline composite VFQ-25 score significantly correlated with the TST value. Multivariate analysis revealed significant associations between the 12-month post-treatment composite VFQ-25 score and the baseline and 12-month post-treatment TNO values. In conclusion, IVR immediately improved stereopsis in CRVO, albeit below normal levels. Stereopsis (not visual acuity) was associated with pre- and post-treatment VR-QOL in patients with CRVO.

scholarly journals Vision-Related Quality of Life and Subscale Items Following Intravitreal Ranibizumab Injections for Central Retinal Vein Occlusion

2021 ◽  
Author(s):  
Fumiki Okamoto ◽  
Tomoya Murakami ◽  
Yoshimi Sugiura ◽  
Shohei Morikawa ◽  
Takahiro Hiraoka ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Central Retinal Vein Occlusion ◽  
Visual Function ◽  
Intravitreal Ranibizumab ◽  
Vein Occlusion ◽  
Before And After ◽  
Related Quality ◽  
Normal Controls ◽  
Central Retinal Vein

Abstract The aim of this study was to evaluate the vision-related quality of life (VR-QOL) before and after intravitreal ranibizumab injections (IVR) for central retinal vein occlusion (CRVO) and investigate subscale items of VR-QOL in detail. This multicenter, open-label, prospective study included 23 patients with treatment naïve CRVO and 22 age-matched normal controls. VR-QOL was assessed by the 25-Item Visual Function Questionnaire (VFQ-25) before and up to 12 months post-treatment. The VFQ-25 composite score and 12 subscales were compared between groups. The VFQ-25 composite scores in CRVO showed significant improvement throughout the treatment period compared with those at the baseline. The VFQ-25 composite score before and after treatment in CRVO was significantly lower than that in normal controls. The subscale items, including general health, general vision, near activities, social functioning, mental health, role difficulties, dependency, and peripheral vision, in CRVO were significantly lower than those in the normal controls even after treatment. Vision-related QOL was low in patients with CRVO before treatment and improved with IVR. Even after treatment, the values of several subscale items were lower than those in normal controls. Patients with CRVO require treatment aimed at further improving visual function as well as social and psychological care.

scholarly journals Time Course of Changes in Vision-Related Quality of Life following Intravitreal Ranibizumab Treatment for Branch Retinal Vein Occlusion

2021 ◽  
Author(s):  
Shohei Morikawa ◽  
Fumiki Okamoto ◽  
Tomoya Murakami ◽  
Yoshimi Sugiura ◽  
Takahiro Hiraoka ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Healthy Subjects ◽  
Composite Score ◽  
Intravitreal Ranibizumab ◽  
Near Vision ◽  
Vein Occlusion ◽  
Related Quality

Abstract Purpose: To assess the vision-related quality of life (VR-QOL) following intravitreal ranibizumab (IVR) for branch retinal vein occlusion (BRVO) and to evaluate subscale items of the VR-QOL.Methods: In this prospective observational multicenter study, 38 patients who underwent IVR treatment for unilateral BRVO and 28 age-matched healthy subjects were chosen. The 25-item National Eye Institute Visual Function Questionnaire (VFQ-25) and best-corrected visual acuity (BCVA) were examined before and at 3, 6, and 12 months after treatment.Results: The VFQ-25 composite score and BCVA significantly improved from 3 to 12 months after IVR treatment (P < 0.05), such that there was no significant difference between the BRVO and control groups at 12 months. All subscales of the VFQ-25, except “general health,” significantly improved after treatment, while “near vision” and “mental health” were worse than those in healthy subjects (P < 0.05). Patients with superior BRVO had a lower “near vision” score than healthy subjects after treatment (P < 0.05). BCVA in the treated eye and fellow eye had no significant relationship with the VFQ-25 composite score before and after treatment.Conclusions: The VR-QOL of patients with BRVO improved with IVR treatment and was comparable to that of healthy subjects after 12 months. Superior BRVO particularly affected near vision for a low level.

Prospective Study of Intravitreal Ranibizumab as a Treatment for Decreased Visual Acuity Secondary to Central Retinal Vein Occlusion

2009 ◽  
Vol 147 (2) ◽  
pp. 298-306 ◽  
Author(s):  
Richard F. Spaide ◽  
Louis K. Chang ◽  
James M. Klancnik ◽  
Lawrence A. Yannuzzi ◽  
John Sorenson ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Prospective Study ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Intravitreal Ranibizumab ◽  
Vein Occlusion ◽  
Central Retinal Vein

scholarly journals Intravitreal Ranibizumab versus Isovolemic Hemodilution in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: Twelve-Month Results of a Prospective, Randomized, Multicenter Trial

2014 ◽  
Vol 233 (1) ◽  
pp. 8-17 ◽  
Author(s):  
Thomas C. Kreutzer ◽  
Armin Wolf ◽  
Martin Dirisamer ◽  
Rupert W. Strauss ◽  
Paul Foerster ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Intravitreal Ranibizumab ◽  
Isovolemic Hemodilution ◽  
Vein Occlusion ◽  
Group I ◽  
Group Ii ◽  
Central Retinal Vein

Purpose: This is a prospective, randomized, multicenter, investigator-initiated trial to evaluate the 12-month effectiveness of isovolemic hemodilution (IH) with prompt versus deferred intravitreal injections (IVI) of ranibizumab 0.5 mg for the treatment of macular edema secondary to early central retinal vein occlusion (CRVO). Methods: Eyes with macular edema due to CRVO having occurred not more than 8 weeks previously received either monthly ranibizumab IVI in combination with IH (group I, n = 28) or IH alone (group II, n = 30). From month 2 to 12, the patients in both groups could be treated with monthly intravitreal ranibizumab. The main outcome variables were gain of visual acuity and the course of central retinal thickness as measured with optical coherence tomography. Results: At 12 months, eyes in group I on average gained +28.1 (±19.3) letters compared to +25.2 (±20.9) letters in group II (p = 0.326). This result was achieved with significantly fewer injections in group II. Additionally, 30% of the eyes in group II did not need ranibizumab IVI during the 12 months of the trial. Conclusion: Ranibizumab IVI in addition to IH proved to be highly effective in increasing visual acuity and reducing macular edema secondary to CRVO. Initial IH in early CRVO may be a first treatment option in patients anxious about IVI.

Contrast sensitivity and quality of life following intravitreal ranibizumab injection for central retinal vein occlusion

2021 ◽  
pp. bjophthalmol-2021-319863
Author(s):  
Tomoya Murakami ◽  
Fumiki Okamoto ◽  
Yoshimi Sugiura ◽  
Shohei Morikawa ◽  
Yoshifumi Okamoto ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Contrast Sensitivity ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Macular Oedema ◽  
Composite Score ◽  
Vein Occlusion ◽  
The Relationship ◽  
Central Retinal Vein

Synopsis/precisWe investigated the relationship between contrast sensitivity (CS) and vision-related quality of life (VR-QOL) in patients with central retinal vein occlusion following ranibizumab intravitreal injection; CS showed a stronger association with VR-QOL than visual acuity.Background/aimsTo investigate the relationship between CS, VR-QOL and optical coherence tomography (OCT) findings in patients with cystoid macular oedema secondary to central retinal vein occlusion (CRVO-CMO) following intravitreal injection of ranibizumab.MethodsThis was a multicentre, open-label, single-arm, prospective study. The study included 23 patients with CRVO-CMO who were followed up for 12 months after treatment. The best-corrected visual acuity (BCVA), letter contrast sensitivity (LCS) and OCT images were obtained every month. For VR-QOL assessment, the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25) was administered to the patients before treatment and at 3, 6 and 12 months following treatment.ResultsThe LCS and VFQ-25 composite score improved significantly from baseline to 12 months following treatment. The multiple regression analysis revealed that the LCS of the affected eye and BCVA of the fellow eye were related to the VFQ-25 composite score following treatment. The LCS improvement showed a significant correlation with the improvement in the VFQ-25 composite score, whereas the BCVA improvement was not correlated with the improvement in the VFQ-25 composite score. Stepwise multiple regression analyses revealed that, at the time of macular oedema resolution, the distance between the external limiting membrane and retinal pigment epithelium (ELM-RPE) and average ganglion cell-inner plexiform layer (GCIPL) thickness were associated with LCS.ConclusionCS had a stronger association with VR-QOL than with BCVA in patients with CRVO-CMO. With the resolution of macular oedema, CS was associated with ELM-RPE thickness and average GCIPL thickness.

Sign in / Sign up

Export Citation Format

Share Document